JP2008536480A - 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法 - Google Patents

癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法 Download PDF

Info

Publication number
JP2008536480A
JP2008536480A JP2007556309A JP2007556309A JP2008536480A JP 2008536480 A JP2008536480 A JP 2008536480A JP 2007556309 A JP2007556309 A JP 2007556309A JP 2007556309 A JP2007556309 A JP 2007556309A JP 2008536480 A JP2008536480 A JP 2008536480A
Authority
JP
Japan
Prior art keywords
marker
cancer
subject
sample
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007556309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008536480A5 (enExample
Inventor
ロナルド・デピンホ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2008536480A publication Critical patent/JP2008536480A/ja
Publication of JP2008536480A5 publication Critical patent/JP2008536480A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2007556309A 2005-02-17 2006-02-17 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法 Pending JP2008536480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65422705P 2005-02-17 2005-02-17
US69006405P 2005-06-13 2005-06-13
PCT/US2006/005584 WO2006089087A2 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Publications (2)

Publication Number Publication Date
JP2008536480A true JP2008536480A (ja) 2008-09-11
JP2008536480A5 JP2008536480A5 (enExample) 2009-03-26

Family

ID=36917075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556309A Pending JP2008536480A (ja) 2005-02-17 2006-02-17 癌の同定、評価、予防、および治療用組成物、キット、および方法、ならびに癌の治療法

Country Status (5)

Country Link
US (1) US8168602B2 (enExample)
EP (1) EP1855727A2 (enExample)
JP (1) JP2008536480A (enExample)
CA (1) CA2595699A1 (enExample)
WO (1) WO2006089087A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010239899A (ja) * 2009-04-06 2010-10-28 Teikyo Univ 潰瘍性大腸炎患者の癌化リスクを決定する方法
JP2013521763A (ja) * 2010-02-10 2013-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肺癌検出用唾液バイオマーカー
JP2019003667A (ja) * 2014-03-25 2019-01-10 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ がん遺伝子変異の機能確認におけるｒｎａ解析のためのシステムおよび方法
JP2020071150A (ja) * 2018-10-31 2020-05-07 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
WO2021015234A1 (ja) * 2019-07-24 2021-01-28 国立大学法人東北大学 キメラ分子、医薬組成物、標的核酸の切断方法、及び、標的核酸切断用又は診断用キット

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2008016996A2 (en) * 2006-08-01 2008-02-07 Joslin Diabetes Center, Inc. Methods of modulating metabolic memory
EP2061906B1 (en) * 2006-09-12 2011-08-31 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
CA2688536A1 (en) * 2007-05-21 2008-11-27 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
JP2011001267A (ja) * 2007-10-17 2011-01-06 Univ Of Tokyo 大腸癌治療薬
WO2010121370A1 (en) * 2009-04-20 2010-10-28 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
US8709718B1 (en) 2011-02-12 2014-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method of treating lung cancer
WO2013066641A1 (en) * 2011-10-21 2013-05-10 Chronix Biomedical Colorectal cancer associated circulating nucleic acid biomarkers
EP4361606A3 (en) * 2012-02-03 2024-07-10 California Institute of Technology Signal encoding and decoding in multiplexed biochemical assays
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
MY196837A (en) 2015-12-11 2023-05-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
WO2017127537A1 (en) * 2016-01-19 2017-07-27 Thomas Blumenthal Down syndrome biomarkers and uses thereof
EP3203413A1 (en) * 2016-02-08 2017-08-09 Ecole Polytechnique Federale De Lausanne (Epfl) Method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof
KR20250047324A (ko) 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
CN109125729A (zh) * 2018-09-06 2019-01-04 苏州吉玛基因股份有限公司 与非小细胞肺癌诊疗相关的基因BRD9及其siRNAs和应用
CN110317876A (zh) * 2019-08-02 2019-10-11 苏州宏元生物科技有限公司 一组染色体不稳定变异在制备诊断多发性骨髓瘤、评估预后的试剂或试剂盒中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512984A (ja) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008512984A (ja) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010239899A (ja) * 2009-04-06 2010-10-28 Teikyo Univ 潰瘍性大腸炎患者の癌化リスクを決定する方法
JP2013521763A (ja) * 2010-02-10 2013-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肺癌検出用唾液バイオマーカー
US9689039B2 (en) 2010-02-10 2017-06-27 The Regents Of The University Of California Salivary biomarkers for lung cancer detection
JP2019003667A (ja) * 2014-03-25 2019-01-10 ファイブスリー ジェノミックス， エルエルシーＦｉｖｅ３ Ｇｅｎｏｍｉｃｓ， Ｌｌｃ がん遺伝子変異の機能確認におけるｒｎａ解析のためのシステムおよび方法
JP2020071150A (ja) * 2018-10-31 2020-05-07 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
JP7262736B2 (ja) 2018-10-31 2023-04-24 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
WO2021015234A1 (ja) * 2019-07-24 2021-01-28 国立大学法人東北大学 キメラ分子、医薬組成物、標的核酸の切断方法、及び、標的核酸切断用又は診断用キット

Also Published As

Publication number Publication date
EP1855727A2 (en) 2007-11-21
US8168602B2 (en) 2012-05-01
US20090297525A1 (en) 2009-12-03
WO2006089087A2 (en) 2006-08-24
WO2006089087A9 (en) 2010-02-04
CA2595699A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
US9309564B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8168602B2 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
US7705120B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP5800817B2 (ja) 前立腺癌における再発性遺伝子融合
JP5937017B2 (ja) Ａｌｋ阻害剤に対する自然耐性または獲得耐性を有する癌の同定、評価および治療法
CN1839205B (zh) 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法
JP4733644B2 (ja) 膵臓腺癌の動物モデルおよびその使用
US20100298158A1 (en) Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer
WO2010045470A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US8999633B2 (en) Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
US20120264625A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
Perrone et al. 9p21 locus analysis in high‐risk gastrointestinal stromal tumors characterized for c‐kit and platelet‐derived growth factor receptor α gene alterations
KR20060120652A (ko) 난소암의 확인, 평가, 예방 및 치료를 위한 핵산 분자 및단백질
KR20090027735A (ko) Ｔａｋ1 억제제를 사용한 암 치료 방법
Babjuk et al. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome
Fong et al. Molecular basis of lung carcinogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090206

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090219

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110802

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111227